Click the following Investor.innoventbiocninvestorswebcastsandpresentations
About Innovent Biologics
“Start with Integrity, Succe with Action” Developing c level executive list highquality biopharmaceuticals that ordinary
people can afford is Innovent’s mission and goal. Found in 2011, Innovent Biologics is committ to the
research, development, production and commercialization of innovative drugs in major disease areas
such as oncology, autoimmunity, metabolism, ophthalmology, etc., so that our work can benefit more
lives. The company has 13 products approv for marketing, including sintilimab injection (Daboshu®,
bevacizumab injection ( Dayoutong®, adalimumab injection (Sulixin® , rituximab injection (
Dabohua® , pemigatinib tablets (Dabotan® , orebactinib tablets (Nailike® , ramucirumab injection
(Ciranze®, sepretib capsules ( Ruitu® , ikiorencel injection ( Fucosu®, tolcizumab injection
(Symbile®, floxacin tablets ( Dabot® , pitubutinib tablets ( Jepali® and talentinib adipate capsules (
Dabolu® . At present, there are 4 varieties under review by NMPA, 3 new drug molecules have enter Phase III or key clinical studies, and another 17 new drug varieties have enter clinical research.
The company has enter
Into more than 30 strategic collaborations with international partners including Eli Lilly, Roche, Sanofi,
Adimab, Incyte and MD Anderson Cancer Center. While continuously developing innovative drugs and
pursuing its own development, Innovent Biologics adheres make sure you use a service to the development philosophy of putting
people at the center of economic construction. Over the years, we have always been scientific and kind,
adher to the “patientcenter” principle, car about patients and their families, and actively fulfill our
social responsibilities. The company has initiat and participat in a number of public welfare drug
assistance projects, enabling more and more patients to benefit from the progress of life sciences and to buy and afford highquality biological drugs.
To date, Innovent Biologics
Patient assistance program has benefit more than trust review 200,000 ordinary patients, with the total value of
drug donations reaching RMB 3.6 billion. Innovent Biologics hopes to work with everyone to improve
the development level of China’s biopharmaceutical industry to meet people’s access to micines and their pursuit of a better life and health Click the following.